期刊文献+

多巴丝肼联合普拉克索治疗帕金森综合征的效果观察 被引量:1

Clinical effects of Levodopa and Benserazide hydrochloride combined with Pramipexole in treatment of Parkinson’s syndrome
下载PDF
导出
摘要 目的:观察多巴丝肼联合普拉克索治疗帕金森综合征的临床效果。方法:选取收治的40例帕金森综合征患者为研究对象,采用随机数字表法分为研究组和对照组,每组20例。对照组予多巴丝肼治疗,研究组在对照组基础上联合普拉克索治疗,比较两组治疗前后帕金森病评定量表(UPDRS)评分,临床疗效及治疗后运动功能。结果:治疗后,两组UPDRS评分均低于治疗前,且研究组低于对照组,差异均有统计学意义(P<0.05);研究组治疗总有效率为95.00%,高于对照组的60.00%,差异有统计学意义(P<0.05);研究组左手及右手1 min限时运动次数均多于对照组,差异有统计学意义(P<0.05);研究组10 m步行折返起立耗时及转弯耗时均短于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:多巴丝肼联合普拉克索治疗帕金森综合征,可有效改善患者的临床症状,改善预后。 Objective: To analyze clinical effects of Levodopa and Benserazide hydrochloride combined with Pramipexole in treatment of Parkinson’s syndrome. Methods: 40 patients with Parkinson’s syndrome were selected as the research objects, and divided into control group(n=20) and study group(n=20) by using the random number table method. The control group was treated with Levodopa and Benserazide hydrochloride, while the study group was treated with Pramipexole on the basis of that of the control group. The unified Parkinson’s disease rating scale(UPDRS) score, clinical efficacy, and motor function after the treatment were compared between the two groups. Results: After the treatment, the UPDRS scores of the two groups were lower than those before the treatment;those of the study group were lower than those of the control group;and the differences were statistically significant(P<0.05). The total effective rate in the study group was 95.00%, which was higher than 60.00% in the control group, and the difference was statistically significant(P<0.05). The numbers of 1-minute timed exercise of left hand and right hand in the study group were higher than those in the control group, and the differences were statistically significant(P<0.05). The standing time and turning time for the 10 meters incremental shuttle walking test in the study group were shorter than those in the control group, and the differences were statistically significant(P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusions: Levodopa and Benserazide hydrochloride combined with Pramipexole in the treatment of Parkinson’s syndrome can effectively improve the clinical symptoms and improve the prognosis of these patients.
作者 张坤 ZHANG Kun(Department of Neurology of Dashiqiao Central Hospital,Yingkou 115100 Liaoning,China)
出处 《中国民康医学》 2020年第2期4-5,9,共3页 Medical Journal of Chinese People’s Health
关键词 多巴丝肼 普拉克索 帕金森综合征 临床疗效 Levodopa and Benserazide hydrochloride Pramipexole Parkinson’s syndrome Clinical efficacy
  • 相关文献

参考文献7

二级参考文献58

  • 1吕荣祥.美多巴联合普拉克索治疗帕金森病的有效性及安全性研究[J].中国生化药物杂志,2014,34(3):153-155. 被引量:46
  • 2蒋雨平,王坚,丁正同,邬剑军,陈嬿.原发性帕金森病的诊断标准(2005年)[J].中国临床神经科学,2006,14(1):40-40. 被引量:156
  • 3Dauer WL,Przedborski S.Parkinson's disease:mechanisms and models[J].J Neuron,2003,39(6):889-909.
  • 4Hughes AJ,Daniel SE,Kilford L,et al.Accuracy of clinical diagnosis of idiopathic Parkinson's disease:a clinico-pathological study of100 cases[J].J Neurol Neurosurg Psychiatry,1992,55(3):181-184.
  • 5Den Oudsten BL,Van Heck GL,De Vries J.Quality of life and related concepts in Parkinson's disease:a systematic review[J].J Mov Disord,2007,22(11):1528-1537.
  • 6Jankovic J.Parkinson's disease:clinical features and diagnosis[J].J Neurosurg Psychiatry,2008,79(4):368-376.
  • 7Le WD,Jankovic J.Are dopamine receptor agonists neuro protective in Parkinson's disease[J].J Drugs Aging,2001,18(6):389-396.
  • 8Schapira AH.Neuroprotection and dopamine agonists[J].J Eur J Neurol,2002,9(suppl 3):7-14.
  • 9Hirsch EC.Future drug targets for Parkinson's disease[J].J Bull Acad Natl Med,2012,196(7):1369-1377.
  • 10Lao CL,Kuo YH,Hsieh YT,et al.Intranasal and subcutaneous administration of dopamine D3 receptor agonists functionally restores nigrostriatal dopamine in MPTP-treated mice[J].J Neurotox Res,2013,24(4):523-531.

共引文献152

同被引文献11

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部